ESMO: Merck's Keytruda-chemo combo shows survival 'trend,' but can't top chemo in bladder cancer

Merck’s Keynote-361 study in newly diagnosed metastatic bladder cancer asked a key question: Could adding Keytruda to chemo improve on chemo, the standard of care?

The answer was no.

But “that’s not to say that there was no activity” in the Keytruda arm, Scot Ebbinghaus, Merck VP of clinical research, said.